DKSH has signed  a strategic business partnership with life science company Bayer, to provide comprehensive services for a portion of the Bayer Pharmaceuticals business in Singapore, Malaysia, Thailand and the Philippines.

DKSH Business Unit Healthcare, a Strategic Healthcare Solutions Partner and leading provider of Market Expansion Services for pharmaceutical, over-the-counter (OTC), consumer health and medical device companies, announces a partnership with life science company Bayer. The scope of the partnership covers Bayer cardiovascular products in Singapore, Malaysia, Thailand, and the Philippines, as well as the women's health retail portfolio in Thailand.
A contract signing ceremony between DKSH Healthcare and Bayer Pharmaceuticals - in Singapore

Recognized for delivering sustainable growth for client partners, DKSH has been chosen to implement a Distribution and Promotion alliance business model that provided end-to-end solutions prioritizing healthcare access to patients. With DKSH's deep expertise in cardiovascular therapies, proven engagement with healthcare professionals, robust distribution infrastructure, and integrated commercial and medical affairs capabilities – this collaboration reinforces a significant step forward in continuing patient care and accessibility in the region.

"We are excited about this new partnership with DKSH," stated Ashraf Al-Ouf, Head of Commercial Operations, Bayer Pharmaceuticals APAC. "DKSH's extensive healthcare expertise and robust commercial capabilities in Southeast Asia position them as an ideal partner for us especially in Malaysia, Philippines, Singapore and Thailand. Together, we are well-equipped to navigate the evolving market landscape, drive sustainable growth, and enhance patient outcomes and accessibility in the region."

"We are thrilled to embark on this partnership with Bayer. Each of the four markets have nuances to their healthcare system, and we appreciate that Bayer recognizes DKSH's proven experience in effective commercialization, customer engagement and patient access. We are well aware that they had other potential choices of partners; hence, we are especially excited that Bayer chose to award this partnership to DKSH as they upgrade their go-to-market business model for these brands. We are confident we can help increase patient access while ensuring compliance and quality," said Bijay Singh, Global Head Business Unit Healthcare, Member of the Executive Committee. He added, "By combining our expertise and resources as the leading healthcare commercialization business partner in the region with Bayer's robust portfolio of products, we remain committed to uplifting the entire healthcare ecosystem in the SEA region, delivering better healthcare to all patients in these markets."